The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

ifølge eksperter TV 2 tidligere har talt med. Er der et potentiale i at løsne grebet om EU og USA og i stedet satse på et nordisk samarbejde med mere indflydelse baseret på blandt andet olie ...

On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

By contrast, those taking a placebo experienced weight gain of up to 2.3%. Amycretin's safety profile, according to Novo Nordisk, was consistent with that of medicines of the same type ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...